Impact of Obesity on Serum Levels of Neuropeptide –Y in Type 2 Diabetics in Relation to Glycemic Status
DOI:
https://doi.org/10.31351/vol33iss(4SI)pp282-289Keywords:
Neuropeptide Y, obesity, Type 2 diabetes mellitus, HOMA-B, HOMA-IR.Abstract
Obesity by multiple mechanisms can contribute not only to the development of type 2 diabetes mellitus (T2DM) but also by further worsening the patient’s condition. One of these mechanisms may include the disturbances of neuropeptide Y (NPY) serum level which is one of the most powerful orexigenic peptides, that’s produced in large amounts in the hypothalamus, as well as in peripheral adipose tissue. The present study aimed to assess the impact of obesity in type 2 diabetic patients on serum neuropeptide-Y level and its impact on fasting serum glucose and insulin levels. Eighty-seven T2DM patients attending the clinic of The National Center of Diabetes Treatment & Research/Baghdad, were included in this study, had been categorized into; Group (1): 45 patients (19 male, 26 female) obese T2DM patients with BMI (30.5- 44) kg/m2 and age range (31-59) years, and Group (2): Normal body weight T2DM patients with BMI (18.6-24.9) kg/m2, included 42 patients (20 male, 22 female), with age range of (33-60) years .Fasting blood specimens were utilized to measure serum NPY and glycemic markers. Data analysis revealed that fasting serum glucose, HbA1c, homeostatic model assessment of insulin resistance (HOMA-IR) and neuropeptide Y values were significantly elevated (P˂0.001) in group-1 in comparison with group-2, however fasting insulin level and homeostasis model assessment of beta-cell function (HOMA-B) were significantly elevated (P˂0.001) in group-2 compared to group-1. Furthermore, neuropeptide-Y was positively correlated with BMI (rho=0.670, P˂0.001), fasting serum glucose (rho=0.697, P˂0.001), HbA1c% (rho=0.274, P=0.010) and HOMA-IR (rho=0.301, P=0.005), whereas it was negatively correlated with fasting serum insulin (rho=-0.296, P=0.005) and HOMA-B (rho=-0.598, P˂0.001).
Conclusion: Elevated serum levels of neuropeptide Y in obese diabetic patient as compared with normal weight diabetic patients suggests that obesity plays a role in serum NYP levels. Furthermore, NPY levels are negatively correlated with serum insulin levels and HOMA-B values; which is indicative of its inhibitory effect on beta cells' ability to secrete insulin in T2DM patients.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Khudair FA, Ali SH, Al-nuaimi AA. Study of Association between RAGE Gene Polymorphism rs2070600 (G82S) and Aspirin Resistance in Coronary Artery Disease Iraqi Patients with and without Type 2 Diabetes. Journal of Pharmaceutical Negative Results. 2022 Oct 7; 13(4):170-82.
Shaban A, Abbas SA, Abed BA. Estimation of Tenascin-C Levels in Iraqi patients with diabetic nephropathy. Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219). 2023 Nov 1; 5(1S):S8-13.
Faris Raheem M, H Ali S, M. A. AL-Nuaimi A, G. Shareef L. Impact of serum vitamin D level on selected bone-related markers in obese- type 2 diabetes patients. F1000Research. 2023 Jan 13; 12:56.
Ali IA, Ali SH. Impact of osteocalcin level on vascular calcification in type 2 diabetics in relation to fibroblast growth factor-23 (FGF-23). Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2018 Dec 6:42-54.
Raheem MF, Ali SH, Shareef LG. Impact of serum levels of vitamin D on lipid profiles, glycemic indices, and insulin resistance in obese type 2 diabetes patients: An observational study. F1000Research. 2022 Sep 6; 11(1002):1002.
Shaheed HS, Ali SH. Association of Carnosinase-1 Gene Polymorphism with Serum Carnosine and Carnosinease-1 Isoform Levels in Type 2 Diabetics with Cardiovascular Diseases in Iraq. Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219). 2023 Jun 25; 4:109-17.
Jabbar TL, Kasim AA. Association of retinol binding protein-4 (RBP4) with glycemia, dyslipidemia, hypertension, and obesity in type 2 diabetic Iraqi patients. Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2020 Dec 30; 29(2):263-70.
Jackson SE, Llewellyn CH, Smith L. The obesity epidemic–Nature via nurture: A narrative review of high-income countries. SAGE open medicine. 2020 Apr; 8:2050312120918265.
Kasim AA, Ataimish AH. The Pathological Mechanisms of Obesity-Related Glomerulopathy : A review article. Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2021 Jun 15; 30(1):22-8.
Chadt A, Scherneck S, Joost HG, Al-Hasani H. Molecular links between obesity and diabetes: “diabesity”. Endotext [Internet]. 2018 Jan 23.
Tang HN, Xiao F, Chen YR, Zhuang SQ, Guo Y, Wu HX, Zhou HD. Higher serum neuropeptide Y levels are associated with metabolically unhealthy obesity in obese chinese adults: A cross-sectional study. Mediators of Inflammation. 2020 Aug 4; 2020.
Chen WC, Liu YB, Liu WF, Zhou YY, He HF, Lin S. Neuropeptide Y is an immunomodulatory factor: direct and indirect. Frontiers in immunology. 2020 Oct 6; 11:580378.
Diaz-delCastillo M, Woldbye DP, Heegaard AM. Neuropeptide Y and its involvement in chronic pain. Neuroscience. 2018 Sep 1; 387:162-9.
Yi M, Li H, Wu Z, Yan J, Liu Q, Ou C, Chen M. A promising therapeutic target for metabolic diseases: neuropeptide Y receptors in humans. Cellular Physiology and Biochemistry. 2018 Dec 22; 45(1):88-107.
Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark A, Metzger BE, Nathan DM, Kirkman MS. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clinical chemistry. 2023 Aug; 69(8):808-68.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972; 18(6):499-502.
Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F, Cadarso-Suarez C, García F, et al. Insulin resistance index (HOMA-IR) levels in a general adult population: curves percentile by gender and age. The EPIRCE study. Diabetes Res Clin Pract. 2011; 94(1):146-55.
Ghasemi A, Tohidi M, Derakhshan A, Hasheminia M, Azizi F, Hadaegh F. Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran Lipid and Glucose Study. Acta diabetologica. 2015 Oct; 52:905-15.
Sitticharoon C, Chatree S, Churintaraphan M. Expressions of neuropeptide Y and Y1 receptor in subcutaneous and visceral fat tissues in normal weight and obese humans and their correlations with clinical parameters and peripheral metabolic factors. Regulatory Peptides. 2013 Aug 10; 185:65-72.
Guzelkas I, Orbak Z, Doneray H, Ozturk N, Sagsoz N. Serum kisspeptin, leptin, neuropeptide Y, and neurokinin B levels in adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism. 2022 Apr 26; 35(4):481-7.
Singer K, Morris DL, Oatmen KE, Wang T, DelProposto J, Mergian T, Cho KW, Lumeng CN. Neuropeptide Y is produced by adipose tissue macrophages and regulates obesity-induced inflammation. PloS one. 2013 Mar 5; 8(3):e57929.
Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R, and Herzog H. Correction: Corrigenda: Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nature Medicine. 2007 Sep; 13(9):1120-.
Macia L, Yulyaningsih E, Pangon L, Nguyen AD, Lin S, Shi YC, Zhang L, Bijker M, Grey S, Mackay F, Herzog H. Neuropeptide Y1 receptor in immune cells regulates inflammation and insulin resistance associated with diet-induced obesity. Diabetes. 2012 Dec 1; 61(12):3228-38.
Dallman MF, Pecoraro N, Akana SF, La Fleur SE, Gomez F, Houshyar H, Bell ME, Bhatnagar S, Laugero KD, Manalo S. Chronic stress and obesity: a new view of “comfort food”. Proceedings of the National Academy of Sciences. 2003 Sep 30; 100(20):11696-701.
Rasmusson AM, Schnurr PP, Zukowska Z, Scioli E, Forman DE. Adaptation to extreme stress: post-traumatic stress disorder, neuropeptide Y and metabolic syndrome. Experimental Biology and Medicine. 2010 Oct; 235(10):1150-62.
Yang CH, Ann-Onda D, Lin X, Fynch S, Nadarajah S, Pappas EG, Liu X, Scott JW, Oakhill JS, Galic S, Shi Y. Neuropeptide Y1 receptor antagonism protects β-cells and improves glycemic control in type 2 diabetes. Molecular metabolism. 2022 Jan 1; 55:101413.
Siva ZO, Uluduz D, Keskin FE, Erenler F, Balci H, Uygunoglu U, Saip S, Goksan B, Siva A. Determinants of glucose metabolism and the role of NPY in progression of insulin resistance in chronic migraine. Cephalalgia. 2018 Oct; 38(11):1773-81.
Yang CH, Onda DA, Oakhill JS, Scott JW, Galic S, Loh K, Regulation of pancreatic β-cell function by the NPY system. Endocrinology. 2021 Aug 1; 162(8):bqab070.
Sun WW, Zhu P, Shi YC, Zhang CL, Huang XF, Liang SY, Song ZY, Lin S. Current views on neuropeptide Y and diabetes-related atherosclerosis. Diabetes and Vascular Disease Research. 2017 Jul; 14(4):277-84.
Koseci T, Omer KA, Haksoyler V, Yildirim DD, Sezer K. Investigation of the relationship between insulin resistance and neuropeptide Y levels in polycystic ovary syndrome. Marmara Medical Journal. 2019 Jan 1; 32(1):1-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
